Key Takeaways
- • Dialybrid secures €15 million Series A financing to advance clinical development of its Silkothane® Arteriovenous Graft, a three-layered semi-resorbable vascular prosthesis designed for hemodialysis vascular access.
- • Company announces successful first-in-human implant of the novel graft, marking a critical clinical validation milestone for the technology after prior proof-of-concept animal studies demonstrating 100% patency rates.
- • Silkothane® technology leverages a proprietary hybrid material composition combining fibroin and polyurethane that gradually integrates into the patient's body, addressing a significant unmet need in hemodialysis vascular access management.
- • Funding will support continued clinical development and commercialization pathway for the arteriovenous graft platform, positioning Dialybrid to address the substantial global market for reliable hemodialysis vascular access solutions.
Summary
Dialybrid, a medical device company specializing in innovative vascular grafts for hemodialysis, has secured €15 million in Series A funding and announced a successful first-in-human implant of its Silkothane® Arteriovenous Graft. The financing milestone and clinical advancement represent substantial progress for the company's core technology platform addressing critical challenges in hemodialysis vascular access.
The Silkothane® Arteriovenous Graft is engineered as a three-layered semi-resorbable vascular prosthesis constructed from fibroin and polyurethane. The semi-resorbable design represents a novel approach wherein the graft gradually integrates into the patient's body over time, potentially offering superior biocompatibility and durability compared to conventional permanent synthetic grafts. This hybrid material science approach distinguishes the technology within the vascular access market.
The first-in-human implant represents a critical clinical validation milestone, following earlier proof-of-concept studies in an ovine (sheep) model that demonstrated safety and 100% patency rates. This progression from animal models to successful human implantation reduces technical and regulatory risk for the technology platform and strengthens the clinical evidence base supporting further development.
The €15 million Series A capital will fund ongoing clinical development of the Silkothane® platform and preclinical activities supporting the broader product roadmap. Dialybrid's focus on arteriovenous vascular grafts addresses a substantial clinical need, as hemodialysis patients require reliable, durable vascular access with minimal failure rates and reduced reliance on temporary catheter solutions. The company is positioned to advance toward broader clinical trials and eventual commercialization in a market where vascular access complications represent a leading cause of morbidity and healthcare costs among the dialysis population.
The Silkothane® Arteriovenous Graft is engineered as a three-layered semi-resorbable vascular prosthesis constructed from fibroin and polyurethane. The semi-resorbable design represents a novel approach wherein the graft gradually integrates into the patient's body over time, potentially offering superior biocompatibility and durability compared to conventional permanent synthetic grafts. This hybrid material science approach distinguishes the technology within the vascular access market.
The first-in-human implant represents a critical clinical validation milestone, following earlier proof-of-concept studies in an ovine (sheep) model that demonstrated safety and 100% patency rates. This progression from animal models to successful human implantation reduces technical and regulatory risk for the technology platform and strengthens the clinical evidence base supporting further development.
The €15 million Series A capital will fund ongoing clinical development of the Silkothane® platform and preclinical activities supporting the broader product roadmap. Dialybrid's focus on arteriovenous vascular grafts addresses a substantial clinical need, as hemodialysis patients require reliable, durable vascular access with minimal failure rates and reduced reliance on temporary catheter solutions. The company is positioned to advance toward broader clinical trials and eventual commercialization in a market where vascular access complications represent a leading cause of morbidity and healthcare costs among the dialysis population.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.